Literature DB >> 32232405

Very Infrequent Zoledronate Therapy - Somehow Still Promisingly Effective.

Joshua N Farr1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32232405      PMCID： PMC7179998          DOI： 10.1210/clinem/dgaa169

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  8 in total

1.  Fracture Prevention with Zoledronate in Older Women with Osteopenia.

Authors:  Ian R Reid; Anne M Horne; Borislav Mihov; Angela Stewart; Elizabeth Garratt; Sumwai Wong; Katy R Wiessing; Mark J Bolland; Sonja Bastin; Gregory D Gamble
Journal:  N Engl J Med       Date:  2018-10-01       Impact factor: 91.245

2.  Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial.

Authors:  Andrew Grey; Anne Horne; Greg Gamble; Borislav Mihov; Ian R Reid; Mark Bolland
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

3.  Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women.

Authors:  Ian R Reid; Anne M Horne; Borislav Mihov; Angela Stewart; Elizabeth Garratt; Sonja Bastin; Gregory D Gamble
Journal:  J Bone Miner Res       Date:  2019-10-11       Impact factor: 6.741

4.  Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.

Authors:  Andrew Grey; Mark J Bolland; Anne Horne; Diana Wattie; Meaghan House; Greg Gamble; Ian R Reid
Journal:  Bone       Date:  2012-03-24       Impact factor: 4.398

5.  Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men.

Authors:  Mark J Bolland; Anne M Horne; Simon E Briggs; Mark G Thomas; IanR Reid; Greg D Gamble; Andrew Grey
Journal:  J Bone Miner Res       Date:  2019-05-29       Impact factor: 6.741

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

Authors:  Cathleen S Colón-Emeric; Peter Mesenbrink; Kenneth W Lyles; Carl F Pieper; Steven Boonen; Pierre Delmas; Erik F Eriksen; Jay Magaziner
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

8.  Zoledronic acid and clinical fractures and mortality after hip fracture.

Authors:  Kenneth W Lyles; Cathleen S Colón-Emeric; Jay S Magaziner; Jonathan D Adachi; Carl F Pieper; Carlos Mautalen; Lars Hyldstrup; Chris Recknor; Lars Nordsletten; Kathy A Moore; Catherine Lavecchia; Jie Zhang; Peter Mesenbrink; Patricia K Hodgson; Ken Abrams; John J Orloff; Zebulun Horowitz; Erik Fink Eriksen; Steven Boonen
Journal:  N Engl J Med       Date:  2007-09-17       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.